JPWO2020009950A5 - - Google Patents

Claims (33)

A composition comprising cannabidiol (CBD) and glucosamine and / or a pharmaceutically acceptable glucosamine salt in a pharmaceutically acceptable dosage form. The composition according to claim 1, wherein the glucosamine is in the form of a pharmaceutically acceptable salt selected from the group consisting of glucosamine sulfate, glucosamine hydrochloride and / or N-acetylglucosamine. The composition according to claim 1, wherein the glucosamine is in the form of a glucosamine sulfate. The composition according to any one of claims 1 to 3, wherein the CBD is extracted from a plant source. The composition according to any one of claims 1 to 3, wherein the CBD is a synthetic product or a semi-synthetic product. The composition according to any one of claims 1 to 5, further comprising at least one additional active ingredient. The composition of claim 6, wherein the at least one additional active ingredient is selected from the group comprising chondroitin, MSM, boswellia serrata extract (afrapin) or a combination thereof. The composition according to any one of claims 1 to 7, wherein the CBD improves the bioavailability of glucosamine. The composition of claim 6 or 7, wherein the CBD enhances the bioavailability of the at least one active ingredient. The composition according to any one of claims 1 to 9, wherein the CBD and glucosamine have a complementary synergistic effect. The composition of claim 6 or 7, wherein the CBD and the at least one additional active ingredient have a complementary synergistic effect. The composition according to any one of claims 1 to 11, for the treatment of at least one disease, condition, symptom or disorder associated with osteoarthritis. 12. The composition of claim 12, wherein the at least one disease is osteoarthritis. A method of treating a non-human animal in need of treatment of a disease, condition, symptom or disorder associated with osteoarthritis, wherein said method is cannavidiol (CBD) and glucosamine and / or pharmaceutically acceptable glucosamine. A method comprising administering a therapeutically effective amount of a composition comprising salt and a pharmaceutically acceptable dosage form. 14. The method of claim 14, wherein the disease is osteoarthritis. The method according to claim 14 or 15, wherein the glucosamine is a glucosamine sulfate. The method according to any one of claims 14 to 16, wherein the CBD is extracted from a plant source. The method according to any one of claims 14 to 16, wherein the CBD is a synthetic product or a semi-synthetic product. The method of any one of claims 14-18, wherein the composition further comprises at least one additional active ingredient. 19. The method of claim 19, wherein the at least one additional active ingredient is selected from the group comprising chondroitin, MSM, Boswellia serrata extract (afrapin), or a combination thereof. The method according to any one of claims 14 to 20, wherein the CBD is administered at the same time as glucosamine. The method according to any one of claims 14 to 20, wherein the CBD is administered separately from glucosamine. A method of improving the bioavailability of glucosamine in a therapeutic formulation containing an effective amount of glucosamine for the treatment of at least one disease, condition, symptom or disorder associated with a non-human animal osteoarthritis. , A method comprising administering cannavidiol (CBD) in a formulation in a predetermined ratio to glucosamine. 23. The method of claim 23, wherein the CBD is administered simultaneously with glucosamine. 23. The method of claim 23, wherein the CBD is administered separately from glucosamine. The method according to any one of claims 23 to 25, wherein the at least one disease is osteoarthritis. 23. 26. The embodiment of any one of claims 23-26, wherein the glucosamine is in the form of a pharmaceutically acceptable salt selected from the group consisting of glucosamine sulfate, glucosamine hydrochloride, and / or N-acetylglucosamine. Method. 27. The method of claim 27, wherein the glucosamine is in the form of a glucosamine sulfate. The method according to any one of claims 23 to 28, wherein the CBD is extracted from a plant source. The method according to any one of claims 23 to 28, wherein the CBD is a synthetic product or a semi-synthetic product. Cannavidiol (CBD) and glucosamine and / or pharmaceutically acceptable thereof in the manufacture of agents for treating patients in need of treatment of at least one disease, condition, symptom or disorder associated with osteoarthritis. Use of salt in pharmaceutically acceptable dosage forms. 31. The use according to claim 31, wherein the glucosamine is in the form of a pharmaceutically acceptable salt selected from the group consisting of glucosamine sulfate, glucosamine hydrochloride, and / or N-acetylglucosamine. 31. The use according to claim 31, wherein the glucosamine is in the form of a glucosamine sulfate.